JP2018501217A - 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン - Google Patents

統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン Download PDF

Info

Publication number
JP2018501217A
JP2018501217A JP2017529388A JP2017529388A JP2018501217A JP 2018501217 A JP2018501217 A JP 2018501217A JP 2017529388 A JP2017529388 A JP 2017529388A JP 2017529388 A JP2017529388 A JP 2017529388A JP 2018501217 A JP2018501217 A JP 2018501217A
Authority
JP
Japan
Prior art keywords
compound
hcl
formulation
pharmaceutical formulation
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017529388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501217A5 (enExample
Inventor
レミー・ルースリンガー
昌弘 奥山
昌弘 奥山
ナディネ・ノエル
サンドラ・ウェルネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JP2018501217A publication Critical patent/JP2018501217A/ja
Publication of JP2018501217A5 publication Critical patent/JP2018501217A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017529388A 2014-12-02 2015-11-30 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン Pending JP2018501217A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US62/086,691 2014-12-02
US201562248071P 2015-10-29 2015-10-29
US62/248,071 2015-10-29
PCT/US2015/062985 WO2016089766A1 (en) 2014-12-02 2015-11-30 Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020116157A Division JP7069253B2 (ja) 2014-12-02 2020-07-06 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン

Publications (2)

Publication Number Publication Date
JP2018501217A true JP2018501217A (ja) 2018-01-18
JP2018501217A5 JP2018501217A5 (enExample) 2018-12-13

Family

ID=54848909

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017529388A Pending JP2018501217A (ja) 2014-12-02 2015-11-30 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
JP2020116157A Active JP7069253B2 (ja) 2014-12-02 2020-07-06 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
JP2022076280A Pending JP2022105159A (ja) 2014-12-02 2022-05-02 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
JP2024173051A Pending JP2025004090A (ja) 2014-12-02 2024-10-02 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020116157A Active JP7069253B2 (ja) 2014-12-02 2020-07-06 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
JP2022076280A Pending JP2022105159A (ja) 2014-12-02 2022-05-02 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
JP2024173051A Pending JP2025004090A (ja) 2014-12-02 2024-10-02 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン

Country Status (26)

Country Link
US (7) US9458130B2 (enExample)
EP (2) EP3227273B1 (enExample)
JP (4) JP2018501217A (enExample)
KR (1) KR102620681B1 (enExample)
CN (2) CN107567444A (enExample)
AU (4) AU2015355226B2 (enExample)
BR (1) BR112017011555B1 (enExample)
CA (1) CA2968977A1 (enExample)
CL (2) CL2017001376A1 (enExample)
CO (1) CO2017005498A2 (enExample)
DK (1) DK3227273T3 (enExample)
EA (1) EA201791226A1 (enExample)
ES (1) ES2910528T3 (enExample)
HU (1) HUE058212T2 (enExample)
IL (4) IL280052B2 (enExample)
MX (1) MX385586B (enExample)
MY (1) MY185516A (enExample)
PE (1) PE20171646A1 (enExample)
PH (1) PH12017501007B1 (enExample)
PL (1) PL3227273T3 (enExample)
PT (1) PT3227273T (enExample)
SG (1) SG11201704332YA (enExample)
TW (1) TWI694069B (enExample)
UA (1) UA122780C2 (enExample)
WO (1) WO2016089766A1 (enExample)
ZA (1) ZA201703481B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910528T3 (es) 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
EP3463356A1 (en) * 2016-05-25 2019-04-10 Minerva Neurosciences, Inc. Compositions and methods for treating negative symptoms in non-schizophrenic patients
EP3641732A1 (en) * 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
BR112021002654A2 (pt) 2018-08-21 2021-05-04 Minerva Neurosciences, Inc. uso de roluperidona para tratar sintomas e distúrbios negativos, aumentar a neuroplasticidade e promover neuroproteção
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
US12441701B2 (en) * 2019-06-28 2025-10-14 Tapi Czech Industries S.R.O. Solid state forms of roluperidone and salts thereof
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois A method for treating lysosomal storage disease using histatin peptides
US20230255953A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123922A1 (en) * 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
JP2013531072A (ja) * 2010-07-20 2013-08-01 キレナイク・ファーマシューティカルズ，インコーポレーテッド 統合失調症を処置するための環状アミド誘導体の使用の方法
US20140018348A1 (en) * 2012-07-12 2014-01-16 Daniel C. Javitt Composition and Method for Treatment of Depression and Psychosis in Humans

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
KR927002347A (ko) 1989-10-27 1992-09-03 레이몬드 지. 아너 (n-프탈이미도알킬) 피페리딘
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
DE60129210T2 (de) * 2000-02-29 2008-03-20 Mitsubishi Pharma Corp. Zyklische amid-derivate
CA2439097C (en) * 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
TW200716531A (en) 2005-06-06 2007-05-01 Merck Sharp & Dohme Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
ES2914120T3 (es) 2010-07-20 2022-06-07 Minerva Neurosciences Inc Procedimientos de uso de derivados de amida cíclicos para tratar trastornos mediados por el receptor sigma
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US10179776B2 (en) * 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
ES2910528T3 (es) * 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
EP3463356A1 (en) 2016-05-25 2019-04-10 Minerva Neurosciences, Inc. Compositions and methods for treating negative symptoms in non-schizophrenic patients
EP3641732A1 (en) 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
BR112021002654A2 (pt) 2018-08-21 2021-05-04 Minerva Neurosciences, Inc. uso de roluperidona para tratar sintomas e distúrbios negativos, aumentar a neuroplasticidade e promover neuroproteção

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531072A (ja) * 2010-07-20 2013-08-01 キレナイク・ファーマシューティカルズ，インコーポレーテッド 統合失調症を処置するための環状アミド誘導体の使用の方法
WO2012123922A1 (en) * 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
US20140018348A1 (en) * 2012-07-12 2014-01-16 Daniel C. Javitt Composition and Method for Treatment of Depression and Psychosis in Humans

Also Published As

Publication number Publication date
EP4063357A1 (en) 2022-09-28
CN107567444A (zh) 2018-01-09
AU2015355226A1 (en) 2017-06-08
SG11201704332YA (en) 2017-06-29
NZ770365A (en) 2023-10-27
US20160152597A1 (en) 2016-06-02
BR112017011555A2 (pt) 2018-01-09
BR112017011555B1 (pt) 2023-10-03
MX385586B (es) 2025-03-18
AU2020204286A1 (en) 2020-07-16
PH12017501007B1 (en) 2024-07-03
CN111110677A (zh) 2020-05-08
AU2015355226B2 (en) 2020-04-02
AU2023258386A1 (en) 2023-11-23
AU2020204286B2 (en) 2021-06-17
WO2016089766A1 (en) 2016-06-09
IL280052A (en) 2021-03-01
JP7069253B2 (ja) 2022-05-17
IL252347B (en) 2021-01-31
UA122780C2 (uk) 2021-01-06
AU2021229240A1 (en) 2021-10-07
CA2968977A1 (en) 2016-06-09
TWI694069B (zh) 2020-05-21
MY185516A (en) 2021-05-19
PH12017501007A1 (en) 2017-12-18
KR20170106310A (ko) 2017-09-20
IL301320B1 (en) 2024-07-01
IL301320A (en) 2023-05-01
US9458130B2 (en) 2016-10-04
IL280052B2 (en) 2023-09-01
US20180153871A1 (en) 2018-06-07
US20200022968A1 (en) 2020-01-23
DK3227273T3 (da) 2022-05-02
JP2025004090A (ja) 2025-01-14
US9730920B2 (en) 2017-08-15
US20210228561A1 (en) 2021-07-29
HUE058212T2 (hu) 2022-07-28
CL2021000044A1 (es) 2021-06-04
CL2017001376A1 (es) 2018-02-16
US20170042877A1 (en) 2017-02-16
EP3227273B1 (en) 2022-02-09
PL3227273T3 (pl) 2022-05-30
AU2023258386B2 (en) 2025-10-23
TW201632511A (zh) 2016-09-16
JP2020172531A (ja) 2020-10-22
IL252347A0 (en) 2017-07-31
IL313572A (en) 2024-08-01
JP2022105159A (ja) 2022-07-12
US10799493B2 (en) 2020-10-13
MX2017007065A (es) 2017-12-18
US20230201184A1 (en) 2023-06-29
ZA201703481B (en) 2023-12-20
CO2017005498A2 (es) 2017-09-20
EP3227273A1 (en) 2017-10-11
NZ732033A (en) 2023-10-27
US20250195494A1 (en) 2025-06-19
US10258614B2 (en) 2019-04-16
KR102620681B1 (ko) 2024-01-04
AU2021229240B2 (en) 2023-08-24
ES2910528T3 (es) 2022-05-12
PE20171646A1 (es) 2017-11-13
IL280052B1 (en) 2023-05-01
PT3227273T (pt) 2022-04-06
EA201791226A1 (ru) 2017-09-29
IL301320B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP7069253B2 (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
CN115154470B (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
EP3941465B1 (en) Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
NZ770365B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
EA040638B1 (ru) Фармацевтический состав, содержащий 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения психоневрологического заболевания или расстройства сна, способ лечения психоневрологического заболевания или расстройства сна, таблетка и набор
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
BR122023014589B1 (pt) Usos de formulação farmacêutica que compreende di-hidrato de monocloridrato de 2-((1-(2-(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200407